MetaCap

Autolus Therapeutics (AUTL) vs Ocugen (OCGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Autolus Therapeutics (AUTL) has outperformed Ocugen (OCGN) over the past year, losing 26.2% versus a loss of 33.8%. Over five years, AUTL leads with a -85.5% price change compared with -88.1% for OCGN. Ocugen is the larger company by market cap ($260.6 million vs $241.7 million), about 1.1 times the size, while Autolus Therapeutics is growing revenue faster (+644.9% vs +8.8%).

Autolus Therapeutics converts more of its revenue into profit, with a net margin of -381.4% versus -1537.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AUTL-26.24%OCGN-33.80%
+121%+37%-47%
Nov 21, 20251 yearNov 20, 2026
AUTL-85.41%OCGN-90.05%
+21%-40%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AUTL versus OCGN key metrics
MetricAUTLOCGN
Share price$0.9073$0.7679
Market cap$241.65M$260.55M
1-day change-7.38%+4.79%
YTD return-54.41%-43.12%
1-year return-26.24%-33.80%
5-year return-85.51%-88.09%
EPS (TTM)$-0.96$-0.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$75.39M$4.41M
Revenue growth (YoY)+644.94%+8.83%
Net income (latest FY)$-287.53M$-67.85M
Gross margin-27.83%—
Operating margin-358.87%-1425.70%
Net margin-381.40%-1537.41%
52-week high$2.58$2.73
52-week low$0.896$0.691
Distance from 52-week high-64.83%-71.82%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+821.42%+1484.84%
Average volume2.07M7.34M
Shares outstanding266.34M339.31M
Employees752116
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Autolus Therapeutics is more profitable, keeping -381.4 cents of every revenue dollar as net income versus -1537.4 cents for Ocugen.
  • Autolus Therapeutics grew revenue faster in its latest fiscal year (+644.94% vs +8.83%).

About Autolus Therapeutics

AUTL stock →

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 752 employees

About Ocugen

OCGN stock →

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 116 employees

AUTL vs OCGN FAQ

Which is bigger, Autolus Therapeutics or Ocugen?

Ocugen (OCGN) is larger, with a market capitalization of $260.55M compared with $241.65M for Autolus Therapeutics (AUTL).

Which stock has performed better over the past year, AUTL or OCGN?

AUTL returned -26.24% over the past 12 months, compared with -33.80% for OCGN (price return, excluding dividends). Past performance does not predict future results.

Are Autolus Therapeutics and Ocugen in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons